Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC Wainwright

Key Points

• Coya Therapeutics has received a strong "buy" rating from HC Wainwright, with a target price of $18.00, indicating a potential upside of 162.39% from its current price.
• The company recently reported a quarterly earnings miss, with an earnings per share of ($0.36), compared to analysts' expectations of ($0.22).
• Hedge funds hold 39.75% of Coya Therapeutics' stock, with notable increases in holdings from several investment groups in recent quarters.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright's target price suggests a potential upside of 162.39% from the company's current price.

COYA has been the subject of a number of other reports. Chardan Capital reissued a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 13th. D. Boral Capital reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 13th. Lake Street Capital assumed coverage on Coya Therapeutics in a research note on Wednesday, July 9th. They set a "buy" rating and a $16.00 target price for the company. Finally, Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Coya Therapeutics has a consensus rating of "Buy" and an average price target of $16.50.

Coya Therapeutics Trading Up 4.1%

Coya Therapeutics stock opened at $6.86 on Monday. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The stock has a 50 day moving average of $6.03 and a two-hundred day moving average of $6.08. The stock has a market capitalization of $114.77 million, a price-to-earnings ratio of -5.53 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. Equities analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds have recently bought and sold shares of the company. DME Capital Management LP increased its position in Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock worth $9,434,000 after buying an additional 372,414 shares in the last quarter. Dauntless Investment Group LLC purchased a new position in Coya Therapeutics during the first quarter worth $1,083,000. CM Management LLC increased its position in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company's stock worth $1,294,000 after buying an additional 40,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Coya Therapeutics during the second quarter worth $119,000. Finally, Jane Street Group LLC increased its position in Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock worth $169,000 after buying an additional 13,176 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.